Case Study
Addex Therapeutics: Creating Novel Small Molecule Drugs for Patients with Central Nervous System Diseases
Addex Therapeutics: Creating Novel Small Molecule Drugs for Patients with Central Nervous System Diseases
Addex Therapeutics is a Geneva-based biotechnology company focused on developing novel, orally available small molecule drugs to treat central nervous system disorders. Its research targets conditions such as Parkinson’s disease, epilepsy, Alzheimer’s disease, PTSD, depression, and other neurodegenerative and neurological illnesses with high unmet medical need. Addex specializes in allosteric modulators, which regulate receptor activity indirectly by inducing conformational changes rather than competing at active binding sites. This approach offers potential advantages over traditional orthosteric drugs, including greater target selectivity, reduced off-target effects, and improved safety. Through this innovative mechanism, Addex aims to create more effective and better-tolerated therapies
